1. Home
  2. RDHL

as of 08-10-2026 3:37pm EST

$0.58
$0.00
0.00%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.

Founded: 2009 Country:
Israel
Israel
Employees: N/A City: N/A
Market Cap: 4.2M IPO Year: 2012
Target Price: N/A AVG Volume (30 days): 56.7K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.58 - $2.79 Next Earning Date: 04-27-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): 381.91% Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered RDHL Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 78.14%
78.14%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Redhill Biopharma Ltd. (RDHL)

Raday Gilead

Chief Operating Officer

Sell
RDHL Jul 10, 2026

Avg Cost/Share

$0.00

Shares

14,130,000

Total Value

$1,413.00

Owned After

218,780,000

SEC Form 4

Share on Social Networks: